Petrauskas Vidas, Damaseviciute Ryte, Gulla Aiste
Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-01131 Vilnius, Lithuania.
Center of Visceral Medicine and Translational Research, Faculty of Medicine, Vilnius University, LT-01131 Vilnius, Lithuania.
Medicina (Kaunas). 2025 Mar 28;61(4):623. doi: 10.3390/medicina61040623.
: Pancreatic organoids are a rapidly advancing field of research with new discoveries being made every day. A literature review was performed to answer the question of how relevant 3D pancreatic organoids are for surgery. : We started our investigation by identifying articles in PubMed within the last 5 years using the keywords (("pancreatic organoid", OR "organ-on-a-chip", OR "pancreatic chip" OR "3D culture methods") AND pancreatic surgery). Only English articles were included in this literature review. This literature review was performed in a non-systematic way; articles were chosen without a predetermined protocol of inclusion and were based on the aim of the review. : There are many promising innovations in the field of 3D cultures. Drug sensitivity testing in particular holds great potential for surgical application. For locally advanced PDAC, EUS-FNB obtained cancer tissue can be cultured as organoids, and after 4 weeks, neoadjuvant treatment could be adjusted for each patient individually. Utilizing this approach could increase the number of R0 resections and possibly cure the disease. Furthermore, microfluidic devices, as a platform for pancreatic islet pre-transplant evaluation or cultivation of cells derived from HiPSC in vitro, promise broad application of islet transplantation to T1DM patients in the near future.
胰腺类器官是一个快速发展的研究领域，每天都有新的发现。我们进行了一项文献综述，以回答3D胰腺类器官与手术的相关性问题。
我们通过在过去5年的PubMed中使用关键词（“胰腺类器官”或“芯片上的器官”或“胰腺芯片”或“3D培养方法”）和胰腺手术来识别文章，从而开始我们的研究。本综述仅纳入英文文章。本综述以非系统的方式进行；文章的选择没有预先确定的纳入方案，而是基于综述的目的。
3D培养领域有许多有前景的创新。特别是药物敏感性测试在手术应用方面具有巨大潜力。对于局部晚期胰腺癌，通过超声内镜引导下细针穿刺活检（EUS-FNB）获得的癌组织可培养成类器官，4周后可为每位患者单独调整新辅助治疗方案。采用这种方法可以增加R0切除的数量，并有可能治愈疾病。此外，微流控装置作为胰岛移植前评估或体外培养源自人诱导多能干细胞（HiPSC）的细胞的平台，有望在不久的将来广泛应用于1型糖尿病（T1DM）患者的胰岛移植。
